CAS No. |
1491917-83-9 |
|---|---|
中文名称 |
S-(1-((4-(((1-((S)-38-氨基-34-((4-((((((S)-4,11-二乙基-9-羟基-3,14-二氧代-3,4,12,14-四氢-1H-吡喃[3',4':6,7]吲哚里嗪并[1,2-b]喹啉-4-基)氧)羰基)氧)甲基)苯基)氨基甲酰基)-28,32-二氧代-3,6,9,12,15,18,21,24,30-九氧杂-27,33-二氮杂辛三十八烷基)-1H-1,2,3-三唑-4-基)甲基)氨基甲酰基)环己基)甲基)-2,5-二氧代吡咯烷-3-基)-L-半胱氨酸 |
英文名称 |
S-(1-((4-(((1-((S)-38-amino-34-((4-((((((S)-4,11-diethyl-9-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl)oxy)carbonyl)oxy)methyl)phenyl)carbamoyl)-28,32-dioxo-3,6,9,12,15,18,21,24,30-nonaoxa-27,33-diazaoctatriacontyl)-1H-1,2,3-triazol-4-yl)methyl)carbamoyl)cyclohexyl)methyl)-2,5-dioxopyrrolidin-3-yl)-L-cysteine |
别名 |
Satralizumab Linker;Sacituzumab Govitecan;Sacituzumab govitecan (ADC);Trodelvy |
标准英文名 |
S-(1-((4-(((1-((S)-38-amino-34-((4-((((((S)-4,11-diethyl-9-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl)oxy)carbonyl)oxy)methyl)phenyl)carbamoyl)-28,32-dioxo-3,6,9,12,15,18,21,24,30-nonaoxa-27,33-diazaoctatriacontyl)-1H-1,2,3-triazol-4-yl)methyl)carbamoyl)cyclohexyl)methyl)-2,5-dioxopyrrolidin-3-yl)-L-cysteine |
MDL No. |
MFCD33029327 |
分子式 |
C76H104N12O24S |
分子量 |
1601.80 |
精确分子量 |
1600.70 |
SMILES |
CCC1=C2CN3C(=CC4=C(COC(=O)[C@@]4(CC)OC(=O)OCC4=CC=C(NC(=O)[C@H](CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCN5C=C(CNC(=O)C6CCC(CN7C(=O)CC(SC[C@H](N)C(=O)O)C7=O)CC6)N=N5)C=C4)C3=O)C2=NC2=C1C=C(O)C=C2 |
标准SMILES |
CC[C@@]1(OC(=O)OCC2C=CC(=CC=2)NC(=O)[C@H](CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCN2C=C(CNC(=O)C3CCC(CN4C(=O)C(CC4=O)SC[C@H](N)C(O)=O)CC3)N=N2)C(=O)OCC2C(=O)N3CC4C(=NC5C=CC(O)=CC=5C=4CC)C3=CC1=2 |
用途 |
Sacituzumab govitecan is an antibody-drug conjugate (ADC) developed by Immunomedics for the treatment of solid tumors, including breast cancer and urothelial cancer. |
InChIKey |
ULRUOUDIQPERIJ-PQURJYPBSA-N |
|
|
评论 |
|---|